|
Delayed
Liquidnet
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.40% | - |
| 08-24 | FTSE 100 outperforms as oil price heads lower | AN |
| 08-24 | European Stocks Close Mostly Lower in Monday Trading; US Treasury Secretary Scott Bessent to Give Details on Iran Sanctions | MT |
Company Valuation: GlaxoSmithKline plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 75,753 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | 3.49% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 95,591 | 92,813 | 89,818 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 9.05% | -2.91% | -3.23% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 14.3x | 11.7x | 10.9x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | - | 4.62x | 4.04x | 3.56x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | -2.29x | 0.5x | 1.57x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.23x | 2.13x | 2.07x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.82x | 2.61x | 2.45x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 8.34x | 7.57x | 7.08x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 9.28x | 8.4x | 7.8x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 17.2x | 16x | 13.2x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 5.81% | 6.24% | 7.57% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.6958 | 0.7495 | 0.7831 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.68% | 3.96% | 4.14% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.323 | 1.616 | 1.728 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 52.6% | 46.4% | 45.3% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,936 | 35,515 | 36,639 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,464 | 12,256 | 12,693 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,298 | 11,044 | 11,519 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 5,436 | 6,484 | 6,933 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 19,838 | 17,060 | 14,065 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 18.90 | 18.90 | 18.90 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 4,007,011 | - | - |
| Announcement Date | 2/9/22 | 2/1/23 | 1/31/24 | 2/5/25 | 2/4/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 35.74x | 12.95x | 26.26x | 0.55% | 1,119B | ||
| 30.06x | - | - | 1.99% | 651B | ||
| 33.82x | 7.82x | 16.26x | 2.59% | 468B | ||
| 20.93x | 4.96x | 12.28x | 2.66% | 374B | ||
| 22.59x | 5.81x | 14.4x | 2.75% | 302B | ||
| 21.46x | 4.4x | 12.56x | 2% | 259B | ||
| 27.79x | 7.17x | 12.73x | 2.3% | 238B | ||
| 13.71x | 4.87x | 10.23x | 3.75% | 208B | ||
| -44.65x | 6.45x | 25.18x | 2.26% | 181B | ||
| Average | 17.94x | 6.80x | 16.24x | 2.32% | 422.21B | |
| Weighted average by Cap. | 25.52x | 8.51x | 18.71x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
- Valuation GlaxoSmithKline plc
Select your edition
All financial news and data tailored to specific country editions
















